AGC Biologics is increasing the production capacity of its Copenhagen facility. The company will construct a new building on land adjacent to its current Copenhagen site, adding production floors with 2000L single-use bioreactors, labs and office space.   The total investment for this expansion is estimated to be approximately €160 million ($194.5 million), and the start of operation is scheduled for 2023.    The expansion will more than double AGC Biologics’ single-use bioreactor mamm...